170 related articles for article (PubMed ID: 20137940)
41. Going through the motions: the ATPase cycle of p97.
Pye VE; Dreveny I; Briggs LC; Sands C; Beuron F; Zhang X; Freemont PS
J Struct Biol; 2006 Oct; 156(1):12-28. PubMed ID: 16621604
[TBL] [Abstract][Full Text] [Related]
42. Discovery of 4-anilino-N-methylthieno[3,2-d]pyrimidines and 4-anilino-N-methylthieno[2,3-d]pyrimidines as potent apoptosis inducers.
Kemnitzer W; Sirisoma N; May C; Tseng B; Drewe J; Cai SX
Bioorg Med Chem Lett; 2009 Jul; 19(13):3536-40. PubMed ID: 19464890
[TBL] [Abstract][Full Text] [Related]
43. Vesnarinone suppresses TNFα mRNA expression by inhibiting valosin-containing protein.
Hotta K; Nashimoto A; Yasumura E; Suzuki M; Azuma M; Iizumi Y; Shima D; Nabeshima R; Hiramoto M; Okada A; Sakata-Sogawa K; Tokunaga M; Ito T; Ando H; Sakamoto S; Kabe Y; Aizawa S; Imai T; Yamaguchi Y; Watanabe H; Handa H
Mol Pharmacol; 2013 May; 83(5):930-8. PubMed ID: 23393163
[TBL] [Abstract][Full Text] [Related]
44. P97/CDC-48: proteostasis control in tumor cell biology.
Fessart D; Marza E; Taouji S; Delom F; Chevet E
Cancer Lett; 2013 Aug; 337(1):26-34. PubMed ID: 23726843
[TBL] [Abstract][Full Text] [Related]
45. Werner syndrome protein directly binds to the AAA ATPase p97/VCP in an ATP-dependent fashion.
Indig FE; Partridge JJ; von Kobbe C; Aladjem MI; Latterich M; Bohr VA
J Struct Biol; 2004; 146(1-2):251-9. PubMed ID: 15037256
[TBL] [Abstract][Full Text] [Related]
46. Valosin-containing protein gene mutations: clinical and neuropathologic features.
Guyant-Maréchal L; Laquerrière A; Duyckaerts C; Dumanchin C; Bou J; Dugny F; Le Ber I; Frébourg T; Hannequin D; Campion D
Neurology; 2006 Aug; 67(4):644-51. PubMed ID: 16790606
[TBL] [Abstract][Full Text] [Related]
47. Pathological consequences of VCP mutations on human striated muscle.
Hübbers CU; Clemen CS; Kesper K; Böddrich A; Hofmann A; Kämäräinen O; Tolksdorf K; Stumpf M; Reichelt J; Roth U; Krause S; Watts G; Kimonis V; Wattjes MP; Reimann J; Thal DR; Biermann K; Evert BO; Lochmüller H; Wanker EE; Schoser BG; Noegel AA; Schröder R
Brain; 2007 Feb; 130(Pt 2):381-93. PubMed ID: 16984901
[TBL] [Abstract][Full Text] [Related]
48. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
49. Valosin-containing protein cleavage by granzyme K accelerates an endoplasmic reticulum stress leading to caspase-independent cytotoxicity of target tumor cells.
Guo Y; Chen J; Shi L; Fan Z
J Immunol; 2010 Nov; 185(9):5348-59. PubMed ID: 20876349
[TBL] [Abstract][Full Text] [Related]
50. E74-like factor 2 transactivates valosin-containing protein gene, a gene involved in cancer growth.
Qiu Y; Morii E; Zhang B; Tomita Y; Aozasa K
Exp Mol Pathol; 2008 Jun; 84(3):226-9. PubMed ID: 18544453
[TBL] [Abstract][Full Text] [Related]
51. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.
Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449
[TBL] [Abstract][Full Text] [Related]
52. Should I stay or should I go: VCP/p97-mediated chromatin extraction in the DNA damage response.
Dantuma NP; Acs K; Luijsterburg MS
Exp Cell Res; 2014 Nov; 329(1):9-17. PubMed ID: 25169698
[TBL] [Abstract][Full Text] [Related]
53. The immunoexpression of valosin-containing protein and small VCP-interacting protein in rat ovaries.
Kartal B; Alimoğulları E; Çaylı S
Anat Histol Embryol; 2023 Jul; 52(4):546-551. PubMed ID: 36843060
[TBL] [Abstract][Full Text] [Related]
54. Valosin-containing protein (VCP/p97) is capable of unfolding polyubiquitinated proteins through its ATPase domains.
Song C; Wang Q; Song C; Rogers TJ
Biochem Biophys Res Commun; 2015 Jul; 463(3):453-7. PubMed ID: 26043696
[TBL] [Abstract][Full Text] [Related]
55. Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis.
Yamamoto S; Tomita Y; Hoshida Y; Sakon M; Kameyama M; Imaoka S; Sekimoto M; Nakamori S; Monden M; Aozasa K
Clin Cancer Res; 2004 Jan; 10(2):651-7. PubMed ID: 14760088
[TBL] [Abstract][Full Text] [Related]
56. VCP (p97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line.
Asai T; Tomita Y; Nakatsuka S; Hoshida Y; Myoui A; Yoshikawa H; Aozasa K
Jpn J Cancer Res; 2002 Mar; 93(3):296-304. PubMed ID: 11927012
[TBL] [Abstract][Full Text] [Related]
57. ATPase activity of p97-valosin-containing protein (VCP). D2 mediates the major enzyme activity, and D1 contributes to the heat-induced activity.
Song C; Wang Q; Li CC
J Biol Chem; 2003 Feb; 278(6):3648-55. PubMed ID: 12446676
[TBL] [Abstract][Full Text] [Related]
58. A Fragment-Based Ligand Screen Against Part of a Large Protein Machine: The ND1 Domains of the AAA+ ATPase p97/VCP.
Chimenti MS; Bulfer SL; Neitz RJ; Renslo AR; Jacobson MP; James TL; Arkin MR; Kelly MJ
J Biomol Screen; 2015 Jul; 20(6):788-800. PubMed ID: 25690569
[TBL] [Abstract][Full Text] [Related]
59. Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer.
Wang X; Bai E; Zhou H; Sha S; Miao H; Qin Y; Liu Z; Wang J; Zhang H; Lei M; Liu J; Hai O; Zhu Y
Bioorg Med Chem; 2019 Feb; 27(3):533-544. PubMed ID: 30606672
[TBL] [Abstract][Full Text] [Related]
60. VCP/p97 regulates Beclin-1-dependent autophagy initiation.
Hill SM; Wrobel L; Ashkenazi A; Fernandez-Estevez M; Tan K; Bürli RW; Rubinsztein DC
Nat Chem Biol; 2021 Apr; 17(4):448-455. PubMed ID: 33510452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
